Oxidative stress has been proposed as a potential mechanism for neurodegenerative diseases, such as Alzheimer disease (AD), Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS). In response to oxidative stress, the levels of numerous cytoprotective products are increased via alteration of the Kelch-like ECHassociated protein 1 (Keap1) and NF-E2Yrelated factor 2 (Nrf2) system. One of the Nrf2 targets, p62, has been known to be incorporated into a wide spectrum of cytoplasmic inclusions in neurodegenerative diseases and interact with Keap1. However, it remains unclear whether Keap1 is associated with the pathogenesis of neurodegenerative diseases. In this study, we investigated the relationship between p62 and Keap1 in the brains of patients with AD, PD, dementia with Lewy bodies (DLB), and ALS. Biochemical analyses showed that p62 and Keap1 interacted with each other in AD and DLB brains and were extracted into similar detergent-soluble and -insoluble fractions. Pathologic examination demonstrated that anti-Keap1 antibodies immunostained Lewy bodies in PD and DLB, neurofibrillary tangles in AD, and skeinlike inclusions in ALS. Further analysis showed that the levels of common Nrf2 target genes were increased in AD compared with those in controls. However, there were no statistical significances in the levels of Nrf2 target genes in DLB relative to controls. Our pathologic and biochemical results suggest a molecular basis for stress response to be involved in the formation of cytoplasmic inclusions observed in several neurodegenerative diseases.
INTRODUCTION
The ubiquitin-proteasome system and autophagylysosomal pathway cooperatively play a critical role in cytoplasmic degradation. Deletion of each system leads to behavioral defects, including spatial learning abnormality in 26S-proteasomal deficient mice (1) and abnormal limbclasping reflexes and a reduction in coordinated movement in autophagy-deficient mice (2) . Because ubiquitin-and p62-positive cytoplasmic inclusions are observed in these mice, the cellular degradation system highly contributes to inclusion formation. In particular, autophagy-deficient mice display a higher expression of detoxifying enzymes, such as heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutamate-cysteine ligase modifier subunit (GCLM), suggesting a close relationship between stress responses and degradation dysfunction. In support of this possibility, recent studies have shown that p62 directly binds with Keap1 (3Y6), which is a cullin-3Ybased E3 ubiquitin ligase for NF-E2Yrelated factor 2 (Nrf2) (7) . Under physiologic conditions, Keap1 ubiquitinates Nrf2 and degrades it via the proteasomal system. Under oxidative stress, Keap1 is inactivated, resulting in Nrf2 stabilization and translocation into the nucleus, where it binds to an antioxidant responsive element and activates the transcription of antioxidant and detoxifying genes (8) .
Similarly, in case of tight binding of Keap1 with p62 within cytoplasmic inclusions, inclusion formation potentially leads to the dissociation of the Nrf2-Keap1 complex and, subsequently, activation of Nrf2 target genes. Indeed, p62 and Keap1 doubleYpositive inclusions were observed in more than 25% of human hepatocellular carcinoma (HCC) cases, and accordingly, the expression levels of Nrf2 target genes are increased in most HCC cells (9) . The p62 is incorporated into a wide spectrum of ubiquitin-positive inclusions in neurodegenerative diseases (10Y12). However, it remains unclear whether Keap1 is associated with cytoplasmic inclusions in neurodegenerative diseases.
In this study, we investigated the relationship between p62 and Keap1 in the brains of patients with Alzheimer disease (AD) and dementia with Lewy bodies (DLB). Using frozen human tissues, we found that Keap1 coimmunoprecipitated with p62 in diseased and control brains. Further pathologic analyses showed that Keap1 was clearly colocalized with p62 in cytoplasmic inclusions observed in AD, DLB, Parkinson disease (PD), multiple system atrophy (MSA), and amyotrophic lateral sclerosis (ALS) brains. Moreover, we also tested the gene expression levels of common Nrf2 targets in the brains of AD, DLB, and control patients.
MATERIALS AND METHODS

Antibodies and Reagents
Rat monoclonal antibody against Keap1 (13), rabbit polyclonal antibodies against Keap1 (ProteinTech Group, Inc., Chicago, IL), p62 (MBL, Nagoya, Japan), and A-actin (Sigma, St. Louis, MO), mouse monoclonal antibodies against p62 (BD Biosciences, Franklin Lakes, NJ), and phosphorylated >-synuclein (pSyn no. 64; Wako, Osaka, Japan) were used in this study.
Subjects and Immunohistochemistry
Tissue samples from 45 autopsy cases were obtained from the Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, and the Department of Pathology, Brain Research Institute, University of Niigata, Niigata, Japan. Written informed consent for autopsy, collection of samples, and subsequent analysis was obtained from the patients and the next of kin of the deceased involved in this study. This study was approved by the Institutional Ethics Committee of Hirosaki University Graduate School of Medicine, Hirosaki, Japan. For immunohistochemistry, patients with AD (n = 5), PD (PD stage 4; n = 5) (14), neocortical-type DLB (PD stages 5 and 6; n = 5) (15), MSA (n = 5), or ALS (n = 5) and normal controls (n = 5) were used (Table 1) . For biochemical analysis, brain tissues were dissected at autopsy and rapidly frozen at j70-C. The middle temporal cortices of patients with AD (n = 5), patients with neocortical-type DLB (n = 5), and normal controls (n = 5) were used in this study ( Table 2 ). The diagnoses were neuropathologically confirmed, and each tissue was weighed and homogenized with a 20-fold volume of loading buffer (75 mmol/L Tris-HCl, pH 6.8, 4% sodium dodecyl sulfate [SDS], 25% glycerol, 5% A-mercaptoethanol).
In a routine histologic examination, the brain was fixed with 10% buffered formalin for 3 weeks. Blocks were cut from various cortical and subcortical regions, embedded in paraffin, sectioned, and then stained with hematoxylin and eosin. For immunohistochemistry, 4-Hm-thick sections were cut from the temporal cortex, hippocampus, midbrain, pons, and cerebellum of patients with AD, PD, DLB, and MSA and controls. The spinal cord and motor cortex were also examined in ALS and control subjects. The sections were dehydrated and pretreated with heat retrieval using an autoclave for 10 minutes in 10 mmol/L citrate buffer (pH 6.0) for rabbit anti-Keap1 antibody. The sections were then subjected to immunohistochemical processing using the avidin-biotin-peroxidase complex method with diaminobenzidine (Sigma). In addition, the sections were counterstained with hematoxylin. Double immunofluorescent staining was performed to detect overlapping expression of Keap1 and phosphorylated 
Immunoprecipitation and Immunoblot Analysis
For immunoprecipitation, frozen brain tissues (0.2 g) from AD, DLB, and control subjects were homogenized in immunoprecipitation buffer (20 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, 2 mmol/L MgCl 2 , 0.5% NP-40, 10% glycerol with protease inhibitor cocktail [Complete Mini EDTA-free, Roche Applied Science, Indianapolis, IN]). The protein concentration in lysates was determined using a bicinchoninic acid assay (Pierce, Rockford, IL). Lysates containing equal amounts of proteins (20 mg) were incubated with rabbit antip62 antibody or immunoglobulin G (IgG) alone binding with Protein GYcoupled magnetic beads for 0.5 hours (Invitrogen). After the incubation, the beads were washed 3 times with TBS with 0.1% Tween 20, eluted in loading buffer. Preimmunoprecipitated lysate was diluted 5-fold with immunoprecipitation buffer and used as the input sample. An equal amount of elution was applied to an SDSYpolyacrylamide gel electrophoresis, and the Western blot analysis was performed as previously described (16) . Horseradish peroxidaseYconjugated anti-mouse, anti-rat, or anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) was used as a secondary antibody. Especially, horseradish peroxidaseYconjugated anti-rabbit IgG (TrueBlot(R); eBioscience, San Diego, CA) was used as a secondary antibody for immunoprecipitated samples. Detection was performed according to the protocol provided with the ECL or ECL plus detection system (Amersham Pharmacia Biotech, Piscataway, NJ). Because p62 and Keap1 have a similar molecular weight in protein size, we separately used a membrane for each antibody to detect signals specific to p62 or Keap1. We performed immunoblot analysis at least 3 times and verified the specificity and reproducibility. Data were quantified as described below and statistically analyzed.
The siRNA-Mediated Knockdown on HeLa Cells
The siRNA was purchased from Dharmacon (Lafayette, CO). The siRNA (final concentration 20 nmol/L) for Keap1 (M-012453-00-0005), Nrf2 (M-003755-02-0005), and nontargeted controls (D-001810-10-20) were transfected into cultured cells using Lipofectamine RNAi MAX (Invitrogen). After 48 hours, the cells were harvested and lysed with lysis buffer containing 4% SDS and 5% A-mercaptoethanol.
Fractionation of Brain Extracts
Frozen tissues from the middle temporal cortex of patients with AD (n = 3), DLB (n = 3), and control subjects (n = 3) were weighed and sequentially extracted with buffers of increasing detergent strength using a previously described protocol (17) . Briefly, samples were homogenized with 10 volumes of buffer A (10 mmol/L Tris-HCl, pH 7.5, 1 mmol/L EGTA, 10% sucrose, 0.8 mol/L NaCl) and centrifuged (Fraction 1 [f1]). Afterward, an equal volume of buffer A containing 2% Triton X-100 was added. The samples were then incubated for 30 minutes at 37-C and spun at 100,000 g for 30 minutes Frozen tissues (the temporal cortex) of patients with AD, patients with DLB, and controls were lysed and immunoprecipitated with endogenous p62. The p62 is detected in the preimmunoprecipitated (Lanes 1, 4, and 7) and immunoprecipitated samples with anti-p62 antibody (Lanes 3, 6, and 9) or IgG alone (Lanes 2, 5, and 8). Immunoblottings show that endogenous Keap1 binds to p62 in controls and in patients with AD or DLB. Rat anti-Keap1 antibody is used. The sample number corresponds to that in Table 2 . (E) Keap1 is coimmunoprecipitated with p62 in each sample. Rat anti-Keap1 antibody is used. The sample number corresponds to that in Table 2 . (F) Positive signals shown in (D) and (E) were quantified by the ImageJ software. The ratio of immunoprecipitated p62 or Keap1 volume to p62 or Keap1 input was measured, respectively, in individual samples (no. 11, 12, 15 for control; no. 1, 2, 4 for DLB; no. 6, 8, 9 for AD. Sample number corresponds to that in Table 2 ). These values were combined with respect to each group. Quantitative data show that there are no differences in immunoprecipitated levels of p62 or Keap1 between controls and AD or DLB. The values in controls are defined as 100%.
method. We applied a constant volume of extract in each fraction to SDSYpolyacrylamide gel electrophoresis.
Quantitative Reverse TranscriptionYPolymerase Chain Reaction
Total RNA was extracted from the middle temporal cortex using the RNeasy Lipid Tissue Mini kit (Qiagen, Hilden, Germany), and cDNA was synthesized from 1 Kg total RNA using the PrimeScript II 1st strand cDNA Synthesis Kit (Takara Bio Inc., Otsu, Japan). An aliquot of cDNA was used for gene expression analysis with the SYBR Premix Ex Taq II (Perfect Real Time; Takara Bio, Inc.), and CFX Real-Time PCR Detection System (Bio-Rad, Hercules, CA) was performed using the following primer sets: HO-1 
Quantitative Analysis and Statistical Analysis
A semiquantitative analysis of protein detection was performed by image analysis with the ImageJ software provided by the National Institutes of Health. All of the values were represented as the means T SD. The statistical significance was evaluated using the Student t-test when comparing 2 conditions. A probability value of less than 0.05 (p G 0.05) was considered to be significant.
RESULTS
Keap1 Binding With p62 in the Brains With AD and DLB
We first examined the specificity of antibodies against Keap1. Consistent with previous articles (18Y20), both rat and rabbit anti-Keap1 antibodies specifically recognized endogenous Keap1, as determined by a loss of signals in Keap1-knockdown cells (Fig. 1A) . Because these antibodies detected several bands, Keap1 protein may be posttranslationally modified. These antibodies were used in the following experiments. Immunoblot analyses demonstrated approximately equivalent levels of Keap1 among AD, DLB, and control tissues (n = 5 in each group) (Fig. 1B) . As we previously showed (21), the level of p62 was significantly higher in AD brains than in control brains (p = 0.016; Fig. 1C ). To examine whether p62 binds to Keap1 in the human brain, we immunoprecipitated endogenous p62 using magnetic beads bound to anti-p62 antibody or IgG alone. Immunoblot analyses indicated that endogenous p62 was successfully immunoprecipitated in AD, DLB, and control brains (lanes 3, 6, and 9 in Fig. 1D, top panel) and that Keap1 was coimmunoprecipitated with p62 in all of the brains (lanes 3, 6, and 9 in Fig. 1D, bottom  panel) . To verify the binding and to compare the binding levels of Keap1 with p62 in the brains with AD or DLB relative to controls, we used additional samples and analyzed in the same way. We confirmed that Keap1 was immunoprecipitated with p62 in every sample regardless of the presence or absence of neurodegeneration (Fig. 1E) . Quantitative analysis showed that immunoprecipitated levels of p62 were not statistically altered between controls and AD or DLB. There were also no significant differences in the immunoprecipitated levels of Keap1 between controls and AD or DLB (Fig. 1F) . Similar results were obtained with both anti-Keap1 antibodies. These results clearly indicated that p62 binds to Keap1 in the brain independently of neurologic disease phenotypes.
Keap1 Localization in Various Cytoplasmic Inclusions in Neurodegeneration
The p62 has been known to be incorporated into a wide spectrum of ubiquitin-positive inclusions in neurodegenerative diseases (10Y12). Next, immunohistochemical studies were performed to address whether Keap1 is localized in cytoplasmic inclusions in AD and DLB brains. In normal controls, anti-Keap1 antibodies weakly stained the neuronal cytoplasm ( Fig. 2A) . Moreover, a lack of Keap1 immunoreactivity was observed in the cytoplasm of glial cells. In the AD brain, neurofibrillary tangles were immunopositive for Keap1 (Fig. 2B) ; however, amyloid plaques were not stained with anti-Keap1 antibodies. In DLB brains, most of the cortical Lewy bodies were positive for Keap1 (Fig. 2C) . Because abnormal >-synuclein accumulation is a cardinal pathologic feature of DLB, PD, and MSA, we further examined brain sections obtained from patients with PD and MSA. Immunohistochemistry showed that anti-Keap1 antibodies intensely immunostained brainstem-type Lewy bodies and pale bodies (Fig. 2D, E) . The latter is considered to be Lewy body precursors (22) . In MSA, neuronal cytoplasmic inclusions were extensively stained with anti-Keap1 antibodies (Fig. 2F) , whereas glial cytoplasmic inclusions were weakly stained (Fig. 2G) . We also examined the spinal cord of ALS patients and found that skeinlike inclusions were Keap1 positive (Fig. 2H) . To verify the colocalization of Keap1 and p62 or >-synuclein, we performed double immunofluorescence. We found that Keap1 was localized in Lewy bodies, which were positive for phosphorylated >-synuclein (Fig. 3) . In addition, Keap1 was also colocalized with p62-positive Lewy bodies.
Importantly, Keap1 was moderately expressed in the core of Lewy bodies, whereas phosphorylated >-synuclein was distributed in the outer part of the Lewy bodies.
Keap1 Property in the Brains With AD and DLB
Several disease-related proteins such as tau and >-synuclein exhibit altered solubility in AD and DLB brains. We investigated whether Keap1 solubility was altered in AD and DLB brains compared with that in controls. Immunoblot analyses showed that Keap1 was mainly extracted in detergentinsoluble fractions (f5) in control, AD, and DLB brains (Fig. 4) . Furthermore, detergent-soluble Keap1 was also present in f3. Interestingly, p62 was mainly extracted into f3 and f5 (Fig. 4) , and p62-and Keap1-positive signals with a similar molecular weight were observed in f1 in AD and, to a lesser extent, in DLB brains. As previously mentioned, CHAPS-soluble fraction (f4) tends to have less protein amount than other fractions by this method. Because we applied a constant volume of extract in each fraction, actin level was lower in f4 than those in other fractions (Fig. 4) .
Increased Levels of Nrf2 Target Genes in the Brains With AD
These pathologic findings raise the possibility of Nrf2 stabilization and suggest that its target genes may be potentially activated in AD and DLB brains. To address this possibility, we assessed the mRNA levels of common Nrf2 targets, such as HO-1, GCLM, and NQO1 in AD, DLB, and control brains. Quantitative reverse transcriptionYpolymerase FIGURE 4. Solubility of Keap1 and p62 in human brains. Frozen tissues were obtained from the temporal cortex of patients with AD, patients with DLB, and control subjects (n = 3 in each group). Sequential biochemical fractionation reveals that Keap1 protein consists of detergent-soluble and -insoluble forms. Note the faint signal at approximately 100 kd in the soluble fraction (f1) in the AD and DLB samples. This signal is positive for Keap1 and p62 (arrowheads). Similar results are observed in other samples of AD, DLB, and control cases. Actin is used as a loading control. Note that f4 contains less amount of protein than other fractions. Rabbit anti-Keap1 antibody is used.
chain reaction (qRT-PCR) demonstrated that the mRNA levels of HO-1 and GCLM were significantly increased 2.5-and 1.4-fold in AD compared with those in control brains, respectively (Fig. 5) . In contrast, there were no statistically significant differences in HO-1 and GCLM mRNA levels between DLB and controls. In addition, there was no significant difference in the levels of NQO1 mRNA between control and AD or DLB brains. The p62 has been reported to be an Nrf2 target (6) . We also found that p62 mRNA levels were increased 1.3-fold (p = 0.046) in AD compared with those in controls.
DISCUSSION
The binding affinity of Keap1 for Nrf2 is decreased when exposed to free radicals and electrophiles, leading to the intranuclear shuttling of Nrf2 and the subsequent transcription of antioxidant responsive elementYdriven genes, including antioxidant and detoxifying enzymes. Thus, Keap1 functions as a sensor for noxious stimuli, such as oxidants and electrophiles. In this study, we demonstrated for the first time that Keap1 is localized in neuronal and glial cytoplasmic inclusions in a variety of neurodegenerative diseases. On the basis of these pathologic findings, we hypothesized that Nrf2 stabilizes and translocates into the nucleus to activate Nrf2 target genes in diseased brains. Thus, we tried to examine nuclear Nrf2 translocation in brain sections. Unfortunately, we could not find any anti-Nrf2 antibodies suitable for immunohistochemistry. Therefore, we assessed the mRNA levels of Nrf2 targets by qRT-PCR in frozen brain tissues. Quantitative RT-PCR revealed that HO-1 and GCLM were significantly increased in AD brains compared with those in controls, and the increased level of HO-1 was consistent with the results obtained from previous studies (23, 24) . Moreover, the mRNA and protein levels of p62 were significantly increased in AD compared with those in controls. Consistent with these results, Bartlett et al (25) reported that p62 protein levels were increased in AD compared with those in controls. In contrast, Du et al (26) demonstrated that p62 protein levels were decreased in AD compared with those in controls. This discrepancy may be caused by the presence of SDS in lysis buffer. Actually, Du et al (26) (Fig. 4) , soluble p62 may be decreased in AD samples compared with that in controls. Instead, detergent-insoluble p62 levels may be increased in AD samples compared with those in controls. Further studies will be needed to clarify this possibility.
Both p62 and the neighbor of brca1 (NBR1) gene function as cargo adapters for autophagic degradation of ubiquitinated substrates, and the levels of both proteins were increased in AD brains compared with those in controls (21) . This finding raises the possibility that the degradation of those proteins is inhibited. Because p62 and NBR1 are incorporated into the autophagosome together with LC3 and are then degraded (27, 28) , the autophagy-lysosomal pathway may be impaired in AD. In support of this possibility, the level of a key regulator protein in autophagy, Beclin 1, was decreased in affected brain regions of AD patients in the early stage of the disease process (29) . In addition, lysosomal enzyme levels were suppressed (30) . Taken together, autophagy-lysosome dysfunction is likely involved in AD progression.
In addition to neurodegenerative diseases, p62 is present in cytoplasmic inclusions found in astrocytoma and various liver diseases such as HCCs (31) . Among them, Inami et al (9) recently reported that p62 together with Keap1 is localized to cytoplasmic inclusions in HCCs. Accordingly, qRT-PCR revealed a marked induction of NQO1 in 8 of 15 cases of HCCs with p62 and Keap1 inclusions. In this study, we were not able to detect significant differences in the levels of common Nrf2-targeted genes between DLB and controls. Why does this not occur in DLB brains? One possible explanation is that neurodegenerative processes are essentially lifelong and are caused by a number of complex factors. However, these facts would also be true of the pathogenesis of AD. Ramsey et al (32) examined Nrf2 localization in AD and PD lesions. Their immunohistochemical results showed that nuclear Nrf2 was more abundant in the substantia nigra in PD. In contrast, Nrf2 was not translocated to the nucleus of hippocampal neurons in AD. These data suggest differences in the degree and timing of oxidative stress exposure between AD and Lewy body disease brains. Furthermore, Nguyen et al (33) generated induced pluripotent stem cells carrying the leucine-rich repeat kinase 2 with a G2019S mutation, which is one of the causative genes for familial PD, and differentiated the cells into dopaminergic neurons. Intriguingly, these neurons were more vulnerable under the oxidative stress condition and exhibited higher levels of several Nrf2 target genes compared with those in controls. Taken together, it is possible that oxidative stress occurs at an early stage of PD pathogenesis and that sustained stress contributes to the dysfunction of the Keap1-Nrf2 system.
Several studies have implicated the involvement of oxidative stress in motor neuron death in ALS patients (34Y39). Recent studies have shown that various oxidative stresses, including H 2 O 2 , heavy metals, and lipids with a cyclopentenone ring, cause posttranslational modifications that affect the pathologic and biochemical properties of TDP-43 (40Y43), a recently identified causative gene for ALS-TDP and frontotemporal lobar degeneration with TDP-43Ypositive inclusions (44, 45) . One lipid mediator, 15-deoxy-$ 12, 14 -prostaglandin J2, forms Michael adducts with cysteine residues of glutathione and various cellular proteins, such as I-JB kinase A (IKKA) and Keap1 (46, 47) , resulting in an altered protein complex and the subsequent activation of inflammation and oxidative stress responses. Most recently, p62 has been demonstrated as a shuttle protein between the cytoplasm and nucleus that binds with TDP-43 in vivo and in vitro (16, 48) . Interestingly, this affinity was strengthened in the presence of ubiquitin. In the presence of various stimuli, such as oxidative stress and proteasomal inhibitors, p62 easily forms aggregates in the cytoplasm, where fragmented TDP-43 exists (49, 50) . Because Keap1 is an E3 ligase for Nrf2 and is mainly a detergentinsoluble protein in the brain (Fig. 4) , Keap1 may exert additional functions, such as TDP-43 ubiquitination in neuronal cytoplasm bearing TDP-43Ypositive cytoplasmic inclusions, in ALS-TDP and frontotemporal lobar degeneration with TDP-43Ypositive inclusions.
Keap1 possesses 2 characteristic domains: the double glycine repeat domain and the BTB (BR-C, ttk and bab) domain. The Keap1 double glycine repeat domain interacts with Nrf2 through the ETGE and DLG motif in Nrf2 (7) . Recent studies have shown that Keap1 binds to p62 through the STGE motif. In this study, we showed that Keap1 was coimmunoprecipitated with p62 in normal human brain, as well as in diseased brains. Independently, Kim et al (51) reported that Keap1 binds to IKKA through an E(T/S)GE motif within IKKA, and Keap1 expression level negatively regulates NF-JB signaling. We showed that Keap1 levels were not different between control and AD or DLB brains; however, Keap1 sequestration within cytoplasmic inclusions potentially leads to disrupted binding with its partners within cells. It is likely that inclusion formation, stress responses, and inflammation are intimately intertwined with one another at the early stage of neurodegenerative diseases.
In conclusion, we provide evidence that Keap1 is localized in cytoplasmic inclusions in various neurodegenerative diseases. Because oxidative stress has been shown in a number of studies to precede the cardinal neuropathologic manifestations in neurodegeneration, the sequestration of Keap1 in cytoplasmic inclusions may be a consequential response against stressors, implying that inclusion formation exerts a cytoprotective role within neurons and glial cells at an early stage of the disease process in which Nrf2 target genes are potentially activated.
